GlassScriptPhysician profile
Mark Klaiman
NPI 1881698488
$2,082.29
in general payments reported to CMS, 2019-2025
21 companies · $352 in 2025
The $352 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $337 · 2020: $274 · 2021: $320 · 2022: $213 · 2023: $339 · 2024: $247 · 2025: $352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $938.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $606.93 | 2019-2022 | |
| Abbvie INC. | $540.61 | 2022-2025 | |
| Boston Scientific Corporation | $138.66 | 2019-2025 | Wavewriter Alpha Prime 16 |
| Lundbeck LLC | $111.55 | 2024-2025 | Vyepti |
| Axogen | $94.92 | 2023 | Avance Nerve Graft |
| Averitas Pharma INC. | $89.55 | 2024-2025 | Qutenza |
| Collegium Pharmaceutical, INC. | $83.98 | 2021-2024 | Belbuca, Xtampza |
| Lilly USA, LLC | $57.19 | 2019-2021 | |
| Bioventus LLC | $54.51 | 2020-2025 | Xcell |
| Amgen INC. | $47.31 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $35.04 | 2020 | |
| Novartis Pharmaceuticals Corporation | $31.32 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $29.46 | 2021 | |
| Abbott Laboratories | $24.90 | 2025 | Eterna |
| Vertex Pharmaceuticals Incorporated | $24.23 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fidia Pharma USA INC. | $20.46 | 2019 | |
| Revance Therapeutics, INC. | $20.27 | 2025 | Daxxify |
| Almatica Pharma LLC | $19.13 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $18.63 | 2019 | |
| Janssen Pharmaceuticals, INC | $18.03 | 2023 | Spravato |
| Medtronic USA, INC. | $15.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Klaiman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.